Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

5.95USD
4:00pm EDT
Change (% chg)

$-0.15 (-2.46%)
Prev Close
$6.10
Open
$6.00
Day's High
$6.30
Day's Low
$5.90
Volume
42,690
Avg. Vol
64,650
52-wk High
$14.90
52-wk Low
$5.90

NERV.OQ

Chart for NERV.OQ

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $259.30
Shares Outstanding(Mil.): 42.51
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -1.08 -- --
ROI: -30.23 2.87 14.88
ROE: -34.99 5.20 16.12

BRIEF-Minerva Neurosciences Q2 loss per share $0.27

* Minerva Neurosciences reports second quarter 2017 financial results and business updates

Aug 03 2017

BRIEF-American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results

* American Journal of Psychiatry publishes Minerva Neurosciences' MIN-101 Phase 2b trial results for treatment of negative symptoms in Schizophrenia

Jul 31 2017

BRIEF-Minerva Neurosciences announces departure of directors

* Announced resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen

Jul 24 2017

BRIEF-Minerva Neurosciences announces departure of directors

* Minerva Neurosciences announces departure of directors Source text for Eikon: Further company coverage:

Jul 24 2017

BRIEF-Minerva Neurosciences prices 5 mln common shares at $7.75 per share

* Minerva neurosciences announces pricing of public offering of common stock

Jun 28 2017

BRIEF-Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

* Minerva announces completion of bridging study to select improved formulation of MIN-101 for use in phase 3 trial for the treatment of negative symptoms in patients with schizophrenia

Jun 22 2017

BRIEF-Minerva Neurosciences enters amendment to co-development and license agreement with Janssen Pharmaceutica NV

* Minerva Neurosciences - on June 13, co entered amendment to co-development and license agreement between company and Janssen Pharmaceutica NV

Jun 14 2017

BRIEF-Minerva announces amended agreement for MIN-202 in insomnia

* Minerva announces amended agreement for MIN-202 in insomnia

May 31 2017

BRIEF-Minerva provides update on phase 3 design and development strategy for MIN-101

* Minerva provides update on phase 3 design and development strategy for MIN-101

May 15 2017

BRIEF-Minerva Neurosciences announces outcome of meeting with FDA

* Minerva announces outcome of end-of-phase 2 meeting with FDA

May 15 2017

Earnings vs. Estimates